Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Nephrology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1412700
This article is part of the Research Topic Onconephrology: Evolving Concepts and Challenges View all 5 articles

Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data

Provisionally accepted
Qiuyu Xu Qiuyu Xu Lin Jiang Lin Jiang Gang Chen Gang Chen *Sanxi Ai Sanxi Ai Gangan Wang Gangan Wang Chunyu Jia Chunyu Jia Jiahui Wang Jiahui Wang Ke Zheng Ke Zheng Bin Zhao Bin Zhao Yan Qin Yan Qin Xuemei Li Xuemei Li
  • Peking Union Medical College Hospital (CAMS), Beijing, China

The final, formatted version of the article will be published soon.

    Poly (ADP-ribose) polymerase inhibitors (PARPis) are emerging targeted therapeutic agents in oncology, primarily indicated for ovarian and metastatic breast cancer. Acute kidney injury (AKI) has been observed in patients undergoing PARPi treatment, while there is still a lack of comprehensive comparisons of AKI associated with different PARPis. Our study aimed to extensively characterize the renal adverse effects (RAEs) of PARPi using real-world data.Disproportionality analysis and Bayesian analysis were employed for data mining to identify suspected RAE cases after different PARPis use within the Food and Drug Administration's Adverse Event Reporting System from January 2004 to September 2023. The time to onset, fatality, and hospitalization rates of PARPi-related RAEs were also investigated.We identified 1,696 PARPi-related RAEs, predominantly affecting patients over 85 (56.31%). Veliparib exhibited a more pronounced association with renal adverse effects compared to others, as indicated by the highest reporting odds ratio (ROR=29.20, 95%CI=8.79-96.97), proportional reporting ratio (PRR=19.80, χ2=72.62), and empirical Bayes geometric mean (EBGM=19.80, the lower 90% one-sided CI=7.25). The median time to RAEs onset was 15 (IQR 6-55.75) days following the initiation of PARPi therapy. PARPirelated RAEs generally led to a 28.15% hospitalization rate and a 4.34% fatality rate.Although the majority present with reversible creatinine elevation, PARPi-related RAEs merits broader attention, given its potential for clinical consequences. We should strive to early identify those individuals who may have irreversible kidney damage. The focus should be directed toward monitoring renal function in individuals receiving PARPi, especially in senile people and those with a predisposition to AKI.

    Keywords: Onco-nephrology, nephrotoxicity, Renal function, ovarian cancer, adverse event reporting system

    Received: 05 Apr 2024; Accepted: 01 Oct 2024.

    Copyright: © 2024 Xu, Jiang, Chen, Ai, Wang, Jia, Wang, Zheng, Zhao, Qin and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Gang Chen, Peking Union Medical College Hospital (CAMS), Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.